RheumNow Podcast - Monitoring Methotrexate Safety (12-6-19)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
News
Biologic Safety Guidelines from the British Society for Rheumatology
In the United Kingdom, NICE has looked to the British Society of Rheumatology (BSR) to develop evidence based guidance on the safe use of biologic DMARDs in patients with inflammatory arthritis.
Secukinumab Improves Enthesitis
Secukinumabs (SEC) effect on enthesitis in psoriatic arthritis (PsA) was studied in the FUTURE 2 and 3 studies and SEC was shown significantly reduced enthesitis by more than 65% within 14 week.
Smoking Cessation Lowers RA Disease Activity and CV Risks
A multinational cross-sectional cohort study suggests that smoking cessation in rheumatoid arthritis (RA) patients is associated with lower disease activity measures, improved lipid profiles and lower rates of cardiovascular (CV) events.
Spondyloarthritis Affects Pregnancy Outcomes
A Danish registy has shown that the the prevalence of Spondyloarthritis (SpA) diagnosed prior to delivery has increased 5 fold in the last two decades and that SpA is associated with an increased risk of adverse pregnancy outcomes (APO).
Apremilast Reduces Oral Ulcers in Behcet's Syndrome
A multinational trial finds a statistically significant number of patients with Behçet's syndrome showed a greater reduction in the number of oral ulcers with apremilast compared with placebo.
#WomenInRheumatology: Is There a Speaker Gender Gap at ACR Meetings?
Recent studies have quantified the gender gap among speakers at academic conferences. The largest study of 181 medical conferences held in North America over one decade found an increase in the proportion of female speakers from 25 to 34% over time, and that the underrepresentation of women was more marked at surgical compared to medical conferences.
IL-17 Inhibitors In Non-Radiographic Axial SpA
This meeting sees new data on using anti-IL-17 agents in non-radiographic axial SpA. Up until now these patients have only had TNF inhibitors available, so data about the efficacy of IL17 inhibitors is really important.
Rheumatic Immune-Related Adverse Events: Not Just Another IrAE
Rheumatic immune-related adverse events can start at almost any time after the commencement after immune checkpoint inhibitor immunotherapy for cancer, and are liable to persist long after the immunotherapy has ceased, according to data presented at ACR 2019 in Atlanta, Georgia.
Systemic JIA-Associated Lung Disease
A disease you’ve never heard of is becoming increasingly common and carries a very poor prognosis.
BMS and Celgene Merge as Amgen Buys Otezla
Bristol-Myers Squibb (BMS) has completed its $74 billion acquisition of Celgene. With the acquisition complete, Celgene is now a wholly-owned subsidiary of BMS. The combined companies have nine products with more than $1 billion in annual sales.
Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout
Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades.
Tapering Of Therapy In RA: Maybe Not So Aggressive Next Time
This ACR has seen some more great work on tapering of therapy in rheumatoid arthritis. It’s a hot topic and one which I get asked about all the time by my patients.
Herpes Zoster Vaccine Update
Shingrix (GSK), the herpes zoster subunit vaccine (a two-shot series), was approved by the FDA in Fall 2018 and is currently approved for use in adults 50 years and older.
RheumNow Podcast –Favorites of ACR 2019 (11.22.19)
Dr. Jack Cush recaps standout presentations and information from ACR 2019 held in Atlanta November 9-12, 2019.
